Last mentioned: Mar 11, 2026
Commercialization Ramp-up
Planned $200M-$250M expenditure for market entry and launch preparation.
Target NDA Submission
Company plans to submit New Drug Application to the FDA by the end of Q2 2026.
Phase 3 Data Release
Belite Bio details 36% lesion growth reduction at Leerink conference.
Belite Bio (BLTE) has reported positive Phase 3 DRAGON trial results for its lead candidate, Tinlarebant, demonstrating a 36% reduction in lesion growth for Stargardt disease. The oral therapy is now positioned for a Q2 2026 NDA submission as the company prepares for a $200M-$250M commercial launch.
This page surfaces every story mentioning Belite Bio across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Belite Bio was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |